// App-Quantinova.ai

2 : Initial Phase 3 Results Of The First (Frontline Investigation Of Lenalidomide + Dexamethasone Versus Standard Thalidomide) Trial (MM-020/IFM 07 01) In Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) Ineligible For Stem Cell Transplantation (SCT)

Researchers

Presenter

  • Thierry Facon

Principal Investigators

  • Angela Dispenzieri

  • Anne Banos

  • Mourad Tiab

  • Michel Delforge

  • James D Cavenagh

  • Catarina Geraldes

  • Je-Jung Lee

  • Christine I. Chen

  • Albert Oriol

  • Javier De La Rubia

  • Lugui Qiu

  • John V. Catalano

  • Darrell J. White

  • Daniel Binder

  • Kenneth C. Anderson

  • Philippe Moreau

  • Michel Attal

  • Robert Knight

  • Guang Chen

  • Jason Van Oostendorp

  • Christian J. Jacques

  • Annette Ervin-Haynes

  • Andrew Belch

  • Lofti Benboubker

  • Cyrille Hulin

  • Michele Cavo

  • Antonello Pinto

  • Katja Weisel

  • Heinz Ludwig

  • Nizar J. Bahlis

Medical Centers

  • Oncoematologia, Istituto Nazionale Tumori Fondazione, Napoli, Italy

  • Centre hospitalier Cote Basque, Bayonne, France

  • Frankston Hospital, Monash University, Frankston, Australia

  • Rheumatology Department, Coimbra University Hospital, Coimbra, Portugal

  • Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada

  • Department of Dermatology Eberhard-Karls University of Tuebingen, Tuebingen, Germany

  • Mayo Clinic Cancer Center, Rochester, MN

  • Dana-Farber Cancer Institute, Boston, MA

  • State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Tianjin, China

  • University of Alberta, Cross Cancer Institute, Edmonton, AB, Canada

  • Service des Maladies du Sang, Hopital Claude Huriez, Lille, France

  • Service -Hematologie, CHU, Nantes, France

  • Service dHematologie, CHU Brabois, Vandoeuvre-les-Nancy, France

  • Department of Medicine I, Wilhelminen Cancer Research Institute, Wilhelminenhospital, Vienna, Vienna, Austria

  • University Hospital of Tours, Tours, France

  • Seragnoli Institute of Hematology, Bologna University School of Medicine, Bologna, Italy

  • University Hospitals Leuven and KU Leuven, Leuven, Belgium

  • Cantonal Hospital Winterthur, Winterthur, Switzerland

  • Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada

  • Hematologie Clinique, CHU Purpan, Toulouse, France

  • Hematology, Hospital Universitario La Fe, Valencia, Spain

  • Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Alexandra General Hospital, Athens, Greece

  • Hospital Germans Trias i Pujol, Barcelona, Spain

  • Guy's Hospital, London, United Kingdom

  • University of Calgary, Calgary, AB, Canada

Locations

  • Canada

  • China

  • Italy

  • Austria

  • Greece

  • Germany

  • Spain

  • Switzerland

  • United Kingdom

  • Australia

  • United States

  • Portugal

  • France

  • Belgium

Companies

  • F. Hoffmann-La Roche

  • Celgene Corporation

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Hematological malignancies

  • Deep vein thrombosis

  • Multiple Myeloma

  • Renal insufficiency

  • Thrombocytopenia

  • Solid malignancies

  • Neutropenia

  • Peripheral neuropathy

  • Venous thrombosis

Biomarkers

  • N/A

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Lenalidomide

  • Thalidomide

  • Prednisone

  • Melphalan

Outcome

  • N/A

Study Design

  • randomized

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved